Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Oxiracetam (ISF2522), a cyclic derivative of gamma-aminobutyric acid (GABA), is utilized for the treatment of cognitive impairments.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 50.00 | |
10 mg | In stock | $ 76.00 | |
25 mg | In stock | $ 118.00 | |
50 mg | In stock | $ 148.00 | |
100 mg | In stock | $ 232.00 | |
200 mg | In stock | $ 349.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 65.00 |
Description | Oxiracetam (ISF2522), a cyclic derivative of gamma-aminobutyric acid (GABA), is utilized for the treatment of cognitive impairments. |
In vitro | In BALB/c mice, Oxiracetam (50 mg/kg i.p.) has been shown to improve avoidance acquisition. Similarly, in rats, pretreatment with Oxiracetam (30 mg/kg) has demonstrated efficacy in ameliorating cognitive deficits induced by trimethyltin. |
Synonyms | ISF2522 |
Molecular Weight | 158.16 |
Formula | C6H10N2O3 |
CAS No. | 62613-82-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (63.23 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Oxiracetam 62613-82-5 Membrane transporter/Ion channel Neuroscience GABA Receptor γ-Aminobutyric acid Receptor ISF 2522 inhibit Inhibitor ISF-2522 Gamma-aminobutyric acid Receptor ISF2522 inhibitor